Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Children's Hospital LA investigators elected into the Society for Pediatric Research

Three investigators from The Saban Research Institute of Children's Hospital Los Angeles have been elected into the prestigious Society for Pediatric Research. Their election to this Society represents peer recognition of their research achievements in pediatrics.

8 Dec 2010

NIH awards Scripps Research $2.35M to study new treatment for obesity

The Scripps Research Institute has been awarded a $2.35 million grant from the National Institutes of Health to study a new way of treating obesity as part of a national consortium with the Dana-Farber Cancer Institute.

8 Dec 2010

32% of UAE residents could have diabetes or prediabetes by 2020

One in three United Arab Emirates (UAE) residents could have diabetes or prediabetes by the end of the decade, according to a new analysis from international health and well-being company UnitedHealth Group, released today at the World Health Care Congress Middle East meeting in Abu Dhabi.

7 Dec 2010

Smoking is common among young adults and children with diabetes, raises risk of heart disease

Cigarette smoking is widespread among children and young adults with diabetes yet few health care providers are counseling children and young adults with diabetes to not smoke or stop smoking, according to a new report from the SEARCH Study Group, published online in the Journal of Pediatrics.

7 Dec 2010

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.

7 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

Merck plans to acquire SmartCells

Today pharmaceutical company, Merck & Co., Inc. announced it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation.

4 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Type 2 diabetics who consume alcohol at increased risk for blurry vision

A new study published in the journal Diabetic Medicine reveals that among patients with type 2 diabetes, alcohol consumption was associated with an increased risk of deterioration of visual acuity.

2 Dec 2010

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Oramed Pharmaceuticals Inc. a developer of oral drug delivery solutions, announces a publication in the Journal of Diabetes Science and Technology's November issue describing evaluation of the company's glucagon-like peptide- (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.

2 Dec 2010

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

2 Dec 2010

Study identifies new genes responsible for early menarche

University of Minnesota School of Public Health researcher Ellen Demerath, Ph.D., is among an international group of researchers that has identified 30 new genes responsible for determining the age of sexual maturation in women. Many of these genes are also known to influence body fatness, obesity, and energy metabolism. Prior to the multi-institutional study, only four genes had been identified as contributing to the process.

1 Dec 2010

Diabetes plays a vital role in regulating brain cholesterol: Research

The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.

1 Dec 2010

Metabolon announces publication of diabetes study in PLoS ONE journal

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting" in PLoS ONE.

1 Dec 2010

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

Study finds boosting glucose levels can reduce aggressive behavior

A spoonful of sugar may be enough to cool a hot temper, at least for a short time, according to new research. A study found that people who drank a glass of lemonade sweetened with sugar acted less aggressively toward a stranger a few minutes later than did people who consumed lemonade with a sugar substitute.

1 Dec 2010

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, Glymera(PB1023), in patients with Type 2 diabetes.

1 Dec 2010

Super-sized World conference to address national health crisis of obesity

A conference at the New York Academy of Sciences on December 9 will convene leading obesity researchers to explore the latest science and policy initiatives addressing the global and national health crisis of obesity.

30 Nov 2010

Case Western Reserve University grants Thermalin Diabetes exclusive license on portfolio of insulin analogs

Case Western Reserve University has granted an exclusive license on a portfolio of insulin analogs to Thermalin Diabetes, LLC, which has assembled more than $3 million to support the development of these important new drugs.

30 Nov 2010